Measurement of oxidized low-density lipoprotein and superoxide dismutase activity in patients with hypertension

Archives of Iranian Medicine

Volumn 12, Issue 2, 2009, Pages 116-120

  Assadpoor Piranfar, Mohammad ^a   Pordal, Amir Hamzeh ^b   Beyranvand, Mohammad Reza ^c  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hypertension; Oxidized LDL; Superoxide dismutase

Indexed keywords

OXIDIZED LOW DENSITY LIPOPROTEIN; SUPEROXIDE DISMUTASE; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; COLORIMETRY; CONTROLLED STUDY; ENZYMATIC ASSAY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME METABOLISM; FEMALE; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; BLOOD; CASE CONTROL STUDY; ENZYMOLOGY; MIDDLE AGED;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTENSION; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; SUPEROXIDE DISMUTASE;

EID: 67649756997     PISSN: 10292977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Victor RG, Kaplan NM. Systemic hypertension: mechanisms and diagnosis. In: Libby P, Bonow RO, Maan DL, Zipes DP, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 8th ed. Philadelphia: Saunders; 2008: 1027.
2. Pickering TG, Ogedegbe G. Epidemiology of hypertension. In: Fuster V, Walsh RA, O'Rourke RA, Poole-Wilson P, eds. Hurst's the Heart. 12th ed. New York: McGraw Hill's; 2008: 1551.
3. Haghdoost AA, Sadeghirad B, Rezazadehkermani M. Epidemiology and heterogeneity of hypertension in Iran: a systematic review. Arch Iran Med. 2008; 11: 444-452.
4. Esteghamati A, Abbasi M, Alikhani S, Gouya MM, Delavari A, Shishehbor MH, et al. Prevalence, awareness, treatment, and risk factors associated with hypertension in the Iranian population: the national survey of risk factors for noncommunicable diseases of Iran. Am J Hypertens. 2008; 21: 620-626.
5. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42: 1206-1252.
6. Kaplan NM. Primary hypertension: pathogenesis. In: Kaplan NM, ed. Kaplan's Clinical Hypertension. 9th ed. Philadelphia: Lippincott Williams and Wilkins; 2006: 50-121.
7. Raij L, Hayakawa H, Coffee K, Guerra J. Effect of doxazosin on endothelial dysfunction in hypercholesterolemic/antioxidant-deficient rats. Am J Hypertens. 1997; 10: 1257-1262.
8. el Hafidi M, Baños G. In vivo plasma lipid oxidation in sugar-induced rat hypertriglyceridemia and hypertension. Hypertension. 1997; 30: 624-628.
9. Pierdomenico SD, Costantini F, Bucci A, Cesare DD, Cuccurullo F, Mezzetti A. Low-density lipoprotein oxidation and vitamins E and C in sustained and whitecoat hypertension. Hypertension. 1998; 31: 621-626.
10. Keidar S. Angiotensin, LDL peroxidation, and atherosclerosis. Life Sci. 1998; 63: 1-11.
11. Toikka JO, Laine H, Ahotupa M, Haapanen A, Viikari JS, Hartiala JJ, et al. Increased arterial intima-media thickness and in vivo LDL oxidation in young men with borderline hypertension. Hypertension. 2000; 36: 929-933.
12. Vaziri ND, Wang XQ, Oveisi F, Rad B. Induction of oxidative stress by glutathione depletion causes severe hypertension in normal rats. Hypertension. 2000; 36: 142-146.
13. Quiñones-Galvan A, Pucciarelli A, Fratta-Pasini A, Garbin U, Franzoni F, Galetta F, et al. Effective blood pressure treatment improves LDL-cholesterol susceptibility to oxidation in patients with essential hypertension. J Intern Med. 2001; 250: 322-326.
14. Lerman LO, Nath KA, Rodriguez-Porcel M, Krier JD, Schwartz RS, Napoli C. et al. Increased oxidative stress in experimental renovascular hypertension. Hypertension. 2001; 37: 541-546.
15. Donmez G, Derici U, Erbas D, Arinsoy T, Onk A, Sindel S, et al. The effects of losartan and enalapril therapies on the levels of nitric oxide, malondialdehyde, and glutathione in patients with essential hypertension. Jpn J Physiol. 2002; 52: 435-440.
16. Brockes C, Locher R, Böttcher A, Schmitz G, Vetter W. LDL-oxidation and -subgroups in normo- and hypertensive patients with and without a family history of hypertension. Vasa. 2002; 31: 75-80.
17. Hodis HN, Hashimoto S, Mack WJ, Sevanian A. Probucol reduces oxysterol formation in hypertensive rabbits. Hypertension. 2000; 36: 436-441.
18. Fukai T, Siegfried MR, Ushio-Fukai M, Griendling KK, Harrison DG. Modulation of extracellular superoxide dismutase expression by angiotensin II and hypertension. Circ Res. 1999; 85: 23-28.
19. Gongora MC, Qin Z, Laude K, Kim HW, McCann L, Folz JR. et al. Role of extracellular superoxide dismutase in hypertension. Hypertension. 2006; 48: 473-481.
20. Ferroni P, Basili S, Paoletti V, Davi G. Endothelial dysfunction and oxidative stress in arterial hypertension. Nutr Metab Cardiovasc Dis. 2006; 16: 222-233.